JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Regeneron Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

569.15 -0.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

566.17

Max

579.36

Belangrijke statistieken

By Trading Economics

Inkomsten

583M

1.4B

Verkoop

647M

3.7B

K/W

Sectorgemiddelde

14.084

34.393

EPS

8.22

Dividendrendement

0.31

Winstmarge

37.86

Werknemers

15,182

EBITDA

39M

1.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+24.19% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.31%

2.54%

Volgende Winsten

30 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

263M

61B

Vorige openingsprijs

569.63

Vorige sluitingsprijs

569.15

Nieuwssentiment

By Acuity

22%

78%

49 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 aug 2025, 11:33 UTC

Winsten

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

1 aug 2025, 13:16 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 12:40 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 10:41 UTC

Winsten

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 aug 2025, 10:41 UTC

Winsten

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 aug 2025, 10:40 UTC

Winsten

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 aug 2025, 10:38 UTC

Winsten

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 aug 2025, 10:37 UTC

Winsten

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 aug 2025, 10:35 UTC

Winsten

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 aug 2025, 10:34 UTC

Winsten

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 aug 2025, 10:33 UTC

Winsten

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 aug 2025, 10:32 UTC

Winsten

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 aug 2025, 10:31 UTC

Winsten

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 aug 2025, 10:31 UTC

Winsten

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Rev $3.68B >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q EPS $12.81 >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Net $1.39B >REGN

13 jun 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 20:45 UTC

Acquisities, Fusies, Overnames

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 jun 2025, 01:41 UTC

Acquisities, Fusies, Overnames

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 mei 2025, 08:58 UTC

Populaire aandelen

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 mei 2025, 08:56 UTC

Marktinformatie

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19 mei 2025, 17:52 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mei 2025, 16:13 UTC

Acquisities, Fusies, Overnames

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19 mei 2025, 14:42 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

Peer Vergelijking

Prijswijziging

Regeneron Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

24.19% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 709.78 USD  24.19%

Hoogste 850 USD

Laagste 543 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Regeneron Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

22 ratings

15

Buy

6

Hold

1

Sell

Technische score

By Trading Central

542.44 / 599.76Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

49 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.